Clevudine therapy for 24 weeks further reduced serum hepatitis B virus DNA levels and increased ALT normalization rates without emergence of viral breakthrough than 12 weeks of clevudine therapy

Kwan Sik Lee, Kwan Soo Byun, Young Hwa Chung, Seung Woon Paik, Joon Yeol Han, Kwon Yoo, Hee Won Yoo, Byung Chul Yoo, Hyo Suk Lee

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Objectives: The objectives of the study were to evaluate the safety and antiviral activity of 24-week treatment with clevudine 30 mg in HBeAg(+) chronic hepatitis B patients. Biochemical and serological responses were also assessed. Method: Twenty-one patients received clevudine 30 mg for 24 weeks and were followed up for another 24 weeks off therapy. Results: Median decreases from baseline in HBV DNA were 4.65 and 1.96 log10 copies/ml at week 24 (end of treatment) and week 48 (24 weeks off therapy), respectively. Analysis of individual data showed that HBV DNA levels were below the lower limit of detection (300 copies/ml) by Amplicor PCR assay in 19, 57, 19 and 0% at week 12, 24, 34 and 48, respectively. The proportion of patients with normal ALT were 67, 81 and 75% at week 24 (end of treatment), 34 and 48 (24 weeks off therapy), respectively. The rates of HBeAg loss were 24 and 20% at week 24 and 48, respectively. No viral breakthrough during treatment was observed. Conclusion: Clevudine 30 mg treatment for 24 weeks was well tolerated and exhibited more potent antiviral activity and a higher ALT normalization rate than 12-week treatment with durable efficacy at week 24 off therapy.

Original languageEnglish
Pages (from-to)296-302
Number of pages7
JournalIntervirology
Volume50
Issue number4
DOIs
Publication statusPublished - 2007 Jul 1

Fingerprint

Hepatitis B virus
DNA
Serum
Therapeutics
Hepatitis B e Antigens
Antiviral Agents
Clevudine
Chronic Hepatitis B
Limit of Detection
Safety
Polymerase Chain Reaction

Keywords

  • Clinical trial
  • Covalently closed circular woodchuck hepatitis virus DNA
  • Hepatitis B virus
  • Viral replication

ASJC Scopus subject areas

  • Virology
  • Infectious Diseases

Cite this

Clevudine therapy for 24 weeks further reduced serum hepatitis B virus DNA levels and increased ALT normalization rates without emergence of viral breakthrough than 12 weeks of clevudine therapy. / Lee, Kwan Sik; Byun, Kwan Soo; Chung, Young Hwa; Paik, Seung Woon; Han, Joon Yeol; Yoo, Kwon; Yoo, Hee Won; Yoo, Byung Chul; Lee, Hyo Suk.

In: Intervirology, Vol. 50, No. 4, 01.07.2007, p. 296-302.

Research output: Contribution to journalArticle

Lee, Kwan Sik ; Byun, Kwan Soo ; Chung, Young Hwa ; Paik, Seung Woon ; Han, Joon Yeol ; Yoo, Kwon ; Yoo, Hee Won ; Yoo, Byung Chul ; Lee, Hyo Suk. / Clevudine therapy for 24 weeks further reduced serum hepatitis B virus DNA levels and increased ALT normalization rates without emergence of viral breakthrough than 12 weeks of clevudine therapy. In: Intervirology. 2007 ; Vol. 50, No. 4. pp. 296-302.
@article{2841dcc20c9b47e2ba8192ee107ce642,
title = "Clevudine therapy for 24 weeks further reduced serum hepatitis B virus DNA levels and increased ALT normalization rates without emergence of viral breakthrough than 12 weeks of clevudine therapy",
abstract = "Objectives: The objectives of the study were to evaluate the safety and antiviral activity of 24-week treatment with clevudine 30 mg in HBeAg(+) chronic hepatitis B patients. Biochemical and serological responses were also assessed. Method: Twenty-one patients received clevudine 30 mg for 24 weeks and were followed up for another 24 weeks off therapy. Results: Median decreases from baseline in HBV DNA were 4.65 and 1.96 log10 copies/ml at week 24 (end of treatment) and week 48 (24 weeks off therapy), respectively. Analysis of individual data showed that HBV DNA levels were below the lower limit of detection (300 copies/ml) by Amplicor PCR assay in 19, 57, 19 and 0{\%} at week 12, 24, 34 and 48, respectively. The proportion of patients with normal ALT were 67, 81 and 75{\%} at week 24 (end of treatment), 34 and 48 (24 weeks off therapy), respectively. The rates of HBeAg loss were 24 and 20{\%} at week 24 and 48, respectively. No viral breakthrough during treatment was observed. Conclusion: Clevudine 30 mg treatment for 24 weeks was well tolerated and exhibited more potent antiviral activity and a higher ALT normalization rate than 12-week treatment with durable efficacy at week 24 off therapy.",
keywords = "Clinical trial, Covalently closed circular woodchuck hepatitis virus DNA, Hepatitis B virus, Viral replication",
author = "Lee, {Kwan Sik} and Byun, {Kwan Soo} and Chung, {Young Hwa} and Paik, {Seung Woon} and Han, {Joon Yeol} and Kwon Yoo and Yoo, {Hee Won} and Yoo, {Byung Chul} and Lee, {Hyo Suk}",
year = "2007",
month = "7",
day = "1",
doi = "10.1159/000105442",
language = "English",
volume = "50",
pages = "296--302",
journal = "Intervirology",
issn = "0300-5526",
publisher = "S. Karger AG",
number = "4",

}

TY - JOUR

T1 - Clevudine therapy for 24 weeks further reduced serum hepatitis B virus DNA levels and increased ALT normalization rates without emergence of viral breakthrough than 12 weeks of clevudine therapy

AU - Lee, Kwan Sik

AU - Byun, Kwan Soo

AU - Chung, Young Hwa

AU - Paik, Seung Woon

AU - Han, Joon Yeol

AU - Yoo, Kwon

AU - Yoo, Hee Won

AU - Yoo, Byung Chul

AU - Lee, Hyo Suk

PY - 2007/7/1

Y1 - 2007/7/1

N2 - Objectives: The objectives of the study were to evaluate the safety and antiviral activity of 24-week treatment with clevudine 30 mg in HBeAg(+) chronic hepatitis B patients. Biochemical and serological responses were also assessed. Method: Twenty-one patients received clevudine 30 mg for 24 weeks and were followed up for another 24 weeks off therapy. Results: Median decreases from baseline in HBV DNA were 4.65 and 1.96 log10 copies/ml at week 24 (end of treatment) and week 48 (24 weeks off therapy), respectively. Analysis of individual data showed that HBV DNA levels were below the lower limit of detection (300 copies/ml) by Amplicor PCR assay in 19, 57, 19 and 0% at week 12, 24, 34 and 48, respectively. The proportion of patients with normal ALT were 67, 81 and 75% at week 24 (end of treatment), 34 and 48 (24 weeks off therapy), respectively. The rates of HBeAg loss were 24 and 20% at week 24 and 48, respectively. No viral breakthrough during treatment was observed. Conclusion: Clevudine 30 mg treatment for 24 weeks was well tolerated and exhibited more potent antiviral activity and a higher ALT normalization rate than 12-week treatment with durable efficacy at week 24 off therapy.

AB - Objectives: The objectives of the study were to evaluate the safety and antiviral activity of 24-week treatment with clevudine 30 mg in HBeAg(+) chronic hepatitis B patients. Biochemical and serological responses were also assessed. Method: Twenty-one patients received clevudine 30 mg for 24 weeks and were followed up for another 24 weeks off therapy. Results: Median decreases from baseline in HBV DNA were 4.65 and 1.96 log10 copies/ml at week 24 (end of treatment) and week 48 (24 weeks off therapy), respectively. Analysis of individual data showed that HBV DNA levels were below the lower limit of detection (300 copies/ml) by Amplicor PCR assay in 19, 57, 19 and 0% at week 12, 24, 34 and 48, respectively. The proportion of patients with normal ALT were 67, 81 and 75% at week 24 (end of treatment), 34 and 48 (24 weeks off therapy), respectively. The rates of HBeAg loss were 24 and 20% at week 24 and 48, respectively. No viral breakthrough during treatment was observed. Conclusion: Clevudine 30 mg treatment for 24 weeks was well tolerated and exhibited more potent antiviral activity and a higher ALT normalization rate than 12-week treatment with durable efficacy at week 24 off therapy.

KW - Clinical trial

KW - Covalently closed circular woodchuck hepatitis virus DNA

KW - Hepatitis B virus

KW - Viral replication

UR - http://www.scopus.com/inward/record.url?scp=34447647491&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34447647491&partnerID=8YFLogxK

U2 - 10.1159/000105442

DO - 10.1159/000105442

M3 - Article

C2 - 17622789

AN - SCOPUS:34447647491

VL - 50

SP - 296

EP - 302

JO - Intervirology

JF - Intervirology

SN - 0300-5526

IS - 4

ER -